| Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting H Tano, M Oroujeni, A Vorobyeva, K Westerlund, Y Liu, T Xu, ... Cancers 13 (3), 500, 2021 | 17 | 2021 |
| Affibody-mediated PNA-based pretargeted cotreatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts M Oroujeni, H Tano, A Vorobyeva, Y Liu, O Vorontsova, T Xu, ... Journal of Nuclear Medicine 63 (7), 1046-1051, 2022 | 11 | 2022 |
| Influence of the position and composition of radiometals and radioiodine labels on imaging of Epcam expression in prostate cancer model using the DARPin Ec1 SM Deyev, T Xu, Y Liu, A Schulga, E Konovalova, J Garousi, SS Rinne, ... Cancers 13 (14), 3589, 2021 | 11 | 2021 |
| Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD … Y Liu, A Vorobyeva, T Xu, A Orlova, A Loftenius, T Bengtsson, P Jonasson, ... Pharmaceutics 13 (6), 839, 2021 | 8 | 2021 |
| Investigation of a pharmacological approach for reduction of renal uptake of radiolabeled ADAPT scaffold protein A Vorobyeva, M Oroujeni, S Lindbo, S Hober, T Xu, Y Liu, SS Rinne, ... Molecules 25 (19), 4448, 2020 | 7 | 2020 |
| Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071 Y Liu, A Vorobyeva, A Orlova, MW Konijnenberg, T Xu, O Bragina, ... Pharmaceutics 14 (5), 1092, 2022 | 6 | 2022 |
| Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells T Xu, Y Liu, A Schulga, E Konovalova, SM Deyev, V Tolmachev, ... Oncology Reports 47 (5), 1-10, 2022 | 6 | 2022 |
| Theranostic pairing: ABY-025/251 targeting HER2 with 68Ga and 188Re—Minimized radioligands using Affibody peptide scaffold technology. Y Liu, JB Sorensen, NC Brun, FY Frejd, V Tolmachev Journal of Clinical Oncology 40 (16_suppl), 3093-3093, 2022 | 3 | 2022 |
